Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2020 financial results on Thursday, July 30, 2020 after the close of financial markets. Following the announcement, Company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

Thursday, July 30, 20201:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in peoples lives. ADCETRIS (brentuximab vedotin) and PADCEVTM (enfortumab vedotin-ejfv) use the Companys industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. TUKYSATM (tucatinib), a small molecule tyrosine kinase inhibitor, is approved in certain HER2-positive metastatic breast cancers. The Company is headquartered in the Seattle, Washington area, with locations in California, Switzerland and the European Union. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005173/en/

Contacts

Investors Peggy Pinkston(425) 527-4160ppinkston@seagen.com

Media Monique Greer(425) 527-4641mgreer@seagen.com

Read more from the original source:
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2020 Financial Results on July 30, 2020 - Yahoo Finance